Schurman D J, Kajiyama G, Nagel D A
J Bone Joint Surg Am. 1980;62(4):620-7.
Using a standardized strain of Escherichia coli 06 and a rabbit knee-joint model, we determined the following values: (1) the effective concentrations of amikacin and carbenicillin in vitro against Escherichia coli 06 when used singly or in combination; (2) the levels of each of these antibiotics in serum and synovial fluid after an intramuscular injection; (3) the effectiveness of amikacin in preventing intra-articular infection when it is administered thirty minutes before and six hours after an intra-articular inoculation of the same strain of Escherichia coli; and (4) the synergistic effects of amikacin and carbenicillin in combination both in vitro and in vivo when used together as a single dose six hours after intra-articular bacterial inoculation. Amikacin was much more effective when administered before joint inoculation and the minimum effective (inhibitory) concentrations of amikacin in vitro and in vivo were approximately the same. A synergistic effect of amikacin and carbenicillin in combination was more clearly evident in vitro than in vivo.
In vitro tests such as determinations of the minimum inhibitory concentration and the minimum bactericidal concentration, and the serum bactericidal test, can provide valuable guides for the determination of minimum goals for antibiotic therapy. These in vitro tests were related to concentrations of antibiotics in tissue assessed by in vivo bacterial challenge tests and were found to be predictive of efficacy in vivo.
使用标准化的大肠杆菌06菌株和兔膝关节模型,我们测定了以下数值:(1)阿米卡星和羧苄西林单独或联合使用时对大肠杆菌06的体外有效浓度;(2)肌肉注射后血清和滑液中每种抗生素的水平;(3)在关节内接种相同菌株的大肠杆菌前30分钟和后6小时给予阿米卡星预防关节内感染的有效性;(4)关节内细菌接种后6小时将阿米卡星和羧苄西林联合作为单剂量使用时在体外和体内的协同作用。在关节接种前给予阿米卡星时效果更佳,且其体外和体内的最低有效(抑制)浓度大致相同。阿米卡星和羧苄西林联合使用的协同作用在体外比在体内更明显。
诸如最低抑菌浓度、最低杀菌浓度测定以及血清杀菌试验等体外试验可为确定抗生素治疗的最低目标提供有价值的指导。这些体外试验与通过体内细菌攻击试验评估的组织中抗生素浓度相关,并且发现可预测体内疗效。